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Abstract
When a new health product becomes available, countries have a choice to adopt the product into their national
health systems or to pursue an alternate strategy to address the public health problem. Here, we describe the role
for product development partnerships (PDPs) in supporting this decision-making process. PDPs are focused on
developing new products to respond to health problems prevalent in low and middle income settings. The impact
of these products within public sector health systems can only be realized after a country policy process. PDPs
may be the organizations most familiar with the evidence which assists decision making, and this generally
translates into involvement in international policy development, but PDPs have limited reach into endemic
countries. In a few individual countries, there may be more extensive involvement in tracking adoption activities
and generating local evidence. This local PDP involvement begins with geographical prioritization based on disease
burden, relationships established during clinical trials, PDP in-country resources, and other factors. Strategies
adopted by PDPs to establish a presence in endemic countries vary from the opening of country offices to
engagement of part-time consultants or with long-term or ad hoc committees. Once a PDP commits to support
country decision making, the approaches vary, but include country consultations, regional meetings, formation of
regional, product-specific committees, support of in-country advocates, development of decision-making
frameworks, provision of technical assistance to aid therapeutic or diagnostic guideline revision, and conduct of
stakeholder and Phase 4 studies. To reach large numbers of countries, the formation of partnerships, particularly
with WHO, are essential. At this early stage, impact data are limited. But available evidence suggests PDPs can and
do play an important catalytic role in their support of country decision making in a number of target countries.
Introduction
For health innovations to have their full impact, they
must reach those in need. This job of achieving access
is a multifaceted endeavor [1-3] requiring consideration
of issues such as financing [4], manufacturing [5], pri-
cing [6], international policies [7], regulatory approval
[8], translational research [9], end-user acceptance [10]
and a strategic communication approach to decision
makers [11]. Here we consider country decision making -
t h ep r o c e s sb yw h i c hac o u n t ry weighs evidence and
decides whether or not to adopt a new product into its
national guidelines and practice [12,13]. Such policy deci-
sions are necessary, but not sufficient, for subsequent
implementation and public health impact [14], as has
been shown by the delays from decision to implementa-
tion of artemisinin-based combination therapies for
malaria treatment [15].
Although the policy change process is ultimately con-
trolled by the country, in low and middle income set-
tings in particular there are many other actors who
provide input and can strengthen local decision making
[16]. One such set of actors is the product development
partnerships (PDPs). These not-for-profit organizations
were formed because commercial incentives had proven
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important areas, such as drug development for tubercu-
losis (TB), malaria, sleeping sickness and visceral
leishmaniasis, vaccine development for HIV, TB,
malaria, dengue fever, meningococcal meningitis and
pneumonia, microbicide development for HIV, and
insecticide development for vector-borne diseases [17].
Over the last several years, these not-for-profit organi-
zations have catalyzed the production of an increasing
number of health products designed specifically for use
in low and middle income settings, such as drugs for
malaria and trypanosomiasis and diagnostics for TB.
Although PDPs have been focused primarily on product
development, they share a vision of realizing the public
health impact promised by new products. PDPs have
generally translated this vision into catalytic support
both for global policy change and, in a limited number
of countries, for activities which could lead to decisions
on use, and therefore support uptake and introduction
of the resulting products. Such activities are implemen-
ted in partnership with endemic countries and other
organizations.
Here, we explore how the PDPs can assist in the
country decision making aspect of product introduction.
Although we recognize the leadership of other actors
including, most notably, country stakeholders them-
selves, our primary focus for this article is on the role of
PDPs. Certain other organizations, such as the Hib
Initiative, have focused on product introduction specifi-
cally, rather than on product development; these are
considered more briefly for relevant lessons. After defin-
ing country decision making, we investigate the various
roles for PDPs, how those roles are prioritized geogra-
phically, the partnerships required, and the specific
approaches used by a number of PDPs. This paper pro-
vides a set of baseline insights into support by PDPs for
country decision-making. It will not define exactly what
should be done in each situation, but provides extensive,
concrete examples of what has been done and analyses
why these approaches were chosen. It also summarizes
the initial, as yet limited, data evaluating the impact of
such work by PDPs. Although the role of PDPs in sup-
porting country decision making is still evolving, we
find some themes that we believe will be generally
applicable for future efforts.
How PDPs fit into country decision making
Core and variable contributions by PDPs
A definition of country decision making will be a useful
starting point, before discussing a possible PDP role.
Previously, country decision-making on new health
interventions has been investigated from a variety of
perspectives. This has resulted in decision-making fra-
meworks [14,18-21], guidance on introduction [3,22],
and descriptions of the types of evidence considered
[12,23,24] or the methods [25] or processes [26] used
for considering them. Multi-variate analyses have sug-
gested which interventions are related to faster uptake
[27]. Although some authors have described supportive
roles played by outside actors [16,20,21], in general the
possible mechanisms for PDPs to support country deci-
sion making remain largely undocumented.
Decision-making processes occur within the unique
socio-political and economic context of an individual
country, whereas a multi-country analysis such as this
one must rely instead on broad process categories (see
below). The relative importance of other elements influ-
encing decision-making, such as media pressure, corrup-
tion and politics, may vary greatly from country to
country [28], and therefore are not addressed in detail
here. Furthermore, we acknowledge that in any political
system the use of evidence-based decision making is a
goal, and not always a reality.
For the purposes of this paper, we have adopted a
simplified framework, assuming country decision mak-
ing requires background information (to elicit problem
identification [29]), evidence to feed into decision mak-
ing, and a process to consider that evidence. Within the
information and evidence categories are many sub-
categories to be considered by country stakeholders,
including public health priority, disease burden, efficacy,
quality, safety, comparison with other available interven-
tions, presentation, supply (procurement and distribu-
tion), financial impact, and programmatic strength [22].
The process category includes, critically, the identifica-
tion and convening of a sufficiently broad group of
stakeholders who have the mandate and resources to
identify and review evidence; this group can be under
the aegis of the government (a specific disease control
program, the broader Ministry of Health, the Ministry
of Finance, a specific agency for technical assessment, or
some combination of these agencies) or independent of
but mandated by the government [13,16]. The final
r e s u l ts h o u l db eap o l i c yc o n c l u s i o na n d ,i ft h ed e c i s i o n
is supportive, implementation. At the center of this pro-
cess is the country itself, supported by a range of local
stakeholders and partner organizations.
As noted by Frost and Reich, “the production of
acceptance [is] an active process of social construction,
not a passive process of waiting for various experts to
agree on key elements related to the use of a health
technology” [1]. If this active process is missing or
under-resourced, effective country decision making is
jeopardized. Indeed, many challenges have arisen during
country decision making. For example, malaria regimen
change in Kenya was delayed due to a lack of national
and international standards (e.g., varied criteria for
chloroquine sensitivity and efficacy markers), insufficient
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new drug implementation), no national compendium of
relevant data, uncoordinated local research studies that
could not be compared to each other, and ineffective
mechanisms for communicating research evidence to
sub-national stakeholders. This resulted in national
guideline change happening 6 years after a call for evi-
dence review and 14 years after the first local data on
resistance [30], with the consequence that millions of
patients were treated with ineffective regimens. In the
area of TB regimens, the current data available (e.g., on
drug resistance patterns) are useful for programmatic
monitoring of current TB treatment but leave gaps for
decision-making around future regimen changes [31].
On the process side, there were delays in another
malaria regimen change due to insufficiently broad par-
ticipation in decision making (e.g., exclusion of local
manufacturers, the Ministry of Finance, and sub-
national implementers) [32]. Similarly, the change from
8- to 6-month TB regimens was delayed in high burden
countries not only by insufficient evidence but also, in
some countries, by unclear or non-existent procedures
or bodies to consider regimen change [12].
Table 1 presents examples of how PDPs can contri-
bute to the core activities of country decision making.
These contributions build on the familiarity of PDPs
with the research programs and evidence base surround-
ing a particular intervention.
There are a variety of additional PDP activities that
can support country decision making but are only
important under certain circumstances (Table 2). Such
PDP access strategies and activities are project specific
and focus on identified gaps: an awareness gap requires
burden of disease studies or advocacy; whereas an evi-
dence gap may require a cost-effectiveness study or
operations research. Some of these activities require
substantially more investment by a PDP. Furthermore, it
cannot be assumed that global activities will reach policy
makers in each country.
A number of these PDP activities are focused on capa-
city building for decision making in general, including
the capacity for a country to decide not to adopt a PDP-
related intervention. For example, a PDP can identify
current gaps and highlight future decision-making
needs, thus helping to catalyze the establishment of
decision-making structures or processes [33]. These
capacity building efforts are likely to be insufficient for
health systems in general, however, given the limited
geographic and product foci of PDPs, and the lack of
mandate from the PDPs’ donors for open-ended capa-
city building. For example, the categories in Tables 1
and 2 and the case studies provided below are based on
the PDPs’ analyses of the bottlenecks within a specific
modality and disease area. Thus, the activity of other
organizations to implement broader capacity building
efforts, such as the establishment of National Immuniza-
tion Technical Advisory Groups (NITAGs) [34], will
remain critical and can be complemented by the work
of PDPs.
Table 1 Examples of country decision making activities
Country activity PDP support role
Background information
￿ Define national health priorities. ￿ Conduct research to understand
priority of disease area, generally,
and likely desire for proposed
product, specifically.
￿ Obtain information on the future
products that are likely to become
available.
￿ Disseminate product and pipeline
information.
Process and people
￿ Ensure a decision-making body
(or person) is identified, active, and
has members empowered to make
decisions based upon available
evidence.
￿ Facilitate awareness raising and
transparent information sharing
among appropriate stakeholders.
￿ Define a clear, step-wise and
timely process for country
decision-making in general (in a
particular disease or intervention
area) and then for adoption of
new products specifically.
Evidence base
￿ Define the specific evidence base
required for decision making,
including local data requirements.
￿ Determine what information is
expected to be needed for
national decision-making (e.g.,
what efficacy endpoints).
￿ Make plans to generate this
required local evidence base.
￿ Integrate consideration of these
information needs into R&D
activities. This affects, for example,
clinical trial planning, development
of regulatory strategies, and post-
introduction strategies to monitor
safety and impact.
￿ Assist countries to define data
needs and gaps, including
clarifying if the information (e.g.,
on program and budget impact)
should be generated in a country
or internationally.
￿ Gather and disseminate a
standard evidence package
informing decision making, or see
that others do so. The data should
come from a source or partnership
that is credible to countries.
￿ Train key personnel to respond
to questions about the data or
lack thereof.
￿ Address concerns that are
common across countries (e.g.,
price, cost-effectiveness, ease of
use, source and geography of
manufacturing, and impact on
supply chain and existing program
delivery).
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ating data, and bringing the data to the attention of
country stakeholders, may be an important part of cata-
lyzing decision-making [11]. PDPs are one contributor
to this activity, as part of the complex decision-making
environment described previously. Each of the many sta-
keholders will bring some perspective, history, and per-
ceived conflict. For PDPs, they may be seen as
contributing a product or technology-biased emphasis.
In contrast, a local researcher may emphasize the need
for additional studies for which he or she would be
funded, or a government official may be under pressure
from a politician. It is critical to note that PDPs, to the
authors’ knowledge, do not have direct profit motives,
unlike manufacturers, when supporting decision-making.
The underlying rationale for PDPs is to help address a
public health problem, for which the intervention arising
with PDP support can be evaluated by a country for its
role, or not, as one locally appropriate solution.
Basis in research
Country decision-making, if it is evidence based,
should be a mechanism to link research to policy. For
PDPs, such a link forms most readily in countries
where PDP-sponsored clinical trials are underway. In
turn, a PDP’s access strategy, and in particular its
approach to country decision making, often emerges
from engagement at country level during the clinical
trial stage.
During the clinical trial approval process, PDPs natu-
rally form links with countries via national regulatory
authorities and ethics committees. But it is local
researchers who generally lead the local implementation
of PDP-supported clinical trials. To date, PDPs have
f o u n dt h a ti ti si m p o r t a n tt op r o a c t i v e l ys u p p o r tal i n k
between these local researchers and other endemic
country stakeholders. This link can be through formal
committees from the conception of the project and dur-
ing the clinical trial phase, or via regular, informal brief-
ings. If initiated early enough, this allows the PDP to
share relevant background information with the country,
increase the trust in and interpretability of resulting trial
data, and ensure the product developed meets the coun-
try’s needs. Local stakeholders can become partners in
the project and can help to build country ownership of,
and familiarity with, a product.
Once it is time for a decision, local researchers (rather
than the PDPs) are best suited to present evidence to
local decision makers and communicate directly with a
government agency. Furthermore, it is more credible for
the PDP to engage local stakeholders on technical
grounds, and to provide them with the technical argu-
ments they need so that they (rather than the PDP) can
take part in the later, more political parts of the decision
making process. In countries where no clinical trials are
underway, the scientific and academic community is a
key partner and translator of research findings in policy
discussions.
Table 2 Examples of additional support activities by PDPs
Additional support activity by PDP Situation when needed or not needed
Background information
Investigate disease burden, and share information with policy-makers. Less need if disease is well characterized and recognized, and if there is
already sufficient baseline surveillance to monitor impact.
Prioritize product introduction activities geographically based on disease
burden, resistance patterns, or risk in specific populations.
Less relevant if disease is widespread and resistance patterns and risk
factors vary little.
Process and people
Catalyze the establishment of decision-making structures. More need if bridging two fields in public health (e.g., immunization
and malaria); less need if strong, defined structures already exist.
Support local advocacy or communications activities to inform policy
makers about a disease and/or options for addressing a disease.
Depends on involvement of others who may undertake this, e.g., WHO
and/or global disease partnerships. Global communications cannot be
assumed to reach country level.
Evidence base
Influence key aspects of the product development process that impact
decision-making, such as pricing, supply, financing and regulatory issues,
and demand estimation. Support the development and sharing of
international policies, and of a post-introduction surveillance plan.
Depends on specific role of PDP in a country and in developing the
product.
Generate or compile local evidence required for decision making,
potentially including the funding and/or running of Phase 4 studies or
operations research.
Depends on clearly defined needs from a country, whether the country
can act as a regional or global source of data, and the willingness, local
staffing, and available resources from PDP.
Support countries to make decisions about a complementary mix of
interventions.
Only relevant if other interventions for the disease are widely used or
being considered.
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and local evidence
Ultimately, it is country stakeholders who drive the two
critical processes: defining what evidence base is neces-
sary for product adoption and launch; and making the
decision itself. The extent to which international actors
assist this process depends on the country: it occurs
more in the lowest income countries and less in more
technically experienced, research-intensive countries
[12]. At the country level, as at the global level, the PDP
can provide information on programmatic implications
and a standardized public health case weighing the evi-
dence for and against adoption. This may represent a
time-limited, targeted commitment from a PDP.
Typically, however, passive provision of this informa-
tion is not enough to lead to clear country decisions [1].
Financing solutions are a key additional requirement,
and there is often a need for an organization specifically
responsible for tracking and coordinating all of the
activities needed for access, including those activities
needed before decision makers will reach an adoption
decision. Others have referred to such an organization
as providing the “architecture” for access [1]. PDPs may
either be prominent in this role or it may be taken by
others such as a local research institute, an implement-
ing NGO, or an international partner such as the World
Health Organization (WHO) (see section below on
partnership).
Whichever organization is primarily responsible for
supporting decision-making, they must interact exten-
sively and directly with country stakeholders, particu-
larly in countries identified as potential early adopters.
This is not a role to be undertaken lightly.
The other, often overlapping area in which PDPs may
become more heavily involved is the generation of local
e v i d e n c e .P D P sh a v ea na w a r e n e s so ft h ee v i d e n c ec u r -
rently available, so they can help countries to determine
which data need to be generated at a local level, versus
provided from global studies. To support local pro-
cesses, PDPs can also introduce models that can be
adapted to generate local data for multiple countries
(e.g., the International Vector Control Consortium
(IVCC)’s monitoring tool (see below) and the PATH
Malaria Vaccine Initiative (MVI)’s impact and cost mod-
els). Finally, PDPs can minimize the need to generate
local data by uncovering existing local data at universi-
ties (programs and WHO may be unaware of these
data) and by explaining why certain data were not
needed if they would not affect the final decision.
Some PDPs devote considerable resources to the gen-
eration of local data; others devote almost none. This
variability is determined in part by the earlier gap analy-
sis - local data may or may not exist or be needed. The
effort to generate local data is also determined by how
novel an intervention is, either within its disease arena
(e.g., a malaria vaccine coming into malaria control
raises a number of local data questions) or by the exis-
tence of a program with clear accountability in the
country which is already collecting such data (e.g., TB
programs already hold extensive data on existing treat-
ment regimens).
When PDPs do engage in these local processes, it is
important that they do so with a health system rather
than single product perspective. The PDP should define
how the new intervention will fit with, affect, and
strengthen other aspects of the existing public health
environment, including all current and potential strate-
gies to address a disease. This is how decision-makers in
disease control programs think and they will be more
likely to engage with the PDP if such an approach is
demonstrated [35]. A disease approach can also bring in
allies from other areas that might otherwise be competi-
tors. An example of this is the Introducing New
Approaches and Tools (INAT) sub-working group of
the Stop TB Partnership, which looks at ways to encou-
rage the adoption both of new technologies and of new
guidelines and practices [36]. Finally, if necessary, PDPs
and other partners should facilitate the formation of a
normative decision making process that covers all inter-
ventions in an area, not just those sponsored by the
PDP [16].
The geography of PDP support of country
decision making
Role of international processes
International institutions reach decisions and issue
guidelines that are often precursors to country-level
decision making. For example, WHO recommendation
will be essential for adoption of PDP-related products in
many if not all of the relevant endemic countries. PDPs
generally interact extensively with WHO to discuss what
evidence is available or needs to be generated for the
international guidelines process.
For some new health interventions, there is no speci-
fic, historical pathway for establishing international poli-
cies. This was the case for a candidate malaria vaccine,
so MVI analyzed past WHO policy processes for vac-
cines and malaria interventions, identified data that
could be required for a policy on malaria vaccines, and
considered additional options for adjusting policy pro-
cesses to accommodate a malaria vaccine [7]. PDPs can
support the formation of international advisory and
advocacy boards such as the Pneumococcal Awareness
Council of Experts (PACE) and the All-Party Parliamen-
tary Group on Pneumococcal Disease Prevention in the
UK. These initiatives were instrumental in supporting
the GAVI Alliance investment case and advance market
commitment (AMC). It is reasonable to assume that
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where feasible, will be less costly and more efficient for
international partners than developing new processes.
How many countries can a PDP reach?
The number of individual countries with which a PDP
can expect to interact directly is not clear. It seems
likely that most PDPs would interact significantly with
perhaps 5-8 countries - notably those that have high dis-
ease burdens, are potential early adopters and are coun-
tries where the PDP is supporting clinical trials - but
many PDPs would then rely on existing multilateral,
NGO, and pharmaceutical partners to reach other coun-
tries for detailed work on adoption and implementation.
At one extreme is the PDP-like Hib Initiative, which
worked together with WHO to support directly or indir-
ectly 72 countries [11]. GAVI supported this group with
a four-year, $37 million grant, after noting the existing
15-20 year uptake delay in most low income countries.
The Hib Initiative had no real role in product develop-
ment but was funded to support evidence-driven deci-
sions on Haemophilus influenzae type b (Hib) vaccine
use at global, regional and country levels. Their
approach, which involved engaging directly or indirectly
with a larger number of countries, was seen to be neces-
sary to implement a global recommendation for use of a
long-available product. Substantial savings may be rea-
lized and less engagement needed if appropriate steps -
on financing, global policy and market preparation, for
example - are taken during product development.
Prioritizing countries for access engagement
If a PDP is going to invest significantly in supporting a
country, it first needs to determine which countries are
the highest priority. Prioritization generally considers
two goals, which may or may not overlap: maximizing
final public health impact; and identifying early adop-
ters. Prioritization may also reflect an effort to include
settings reflecting the full range of epidemiologic pat-
terns of the disease (e.g., for malaria).
Prioritizing countries for engagement on access-
related issues is not a science - there is no perfect
answer. Different PDPs are likely to use shorter or
longer lists of criteria in making such decisions. How-
ever, most PDPs will consider a number of the following
criteria, with the more important listed first: prior
engagement via PDP-sponsored trials; high burden of
disease (absolute or reflecting specific patterns of resis-
tance or vulnerability); potential health benefit (e.g.,
based on drug resistance patterns); political stability;
capacity of national program to deliver treatment (e.g.,
focusing new vaccine interventions on those countries
with strong EPI programs); existence of local champions
and openness to change; research capability for a pilot,
which would generate evidence for other countries;
regional importance of country; regulatory capacity and
influence; and availability of other information for deci-
sion making.
WHO regional advisers can also provide prioritization
guidance. In support of the introduction of Hib vaccine,
WHO regional EPI officers helped the Hib Initiative to
identify issues and barriers for each country and define
whether country stakeholders were already including
Hib in their multi-year plans. A country’s application to
the Global Fund to Fight AIDS, TB and Malaria can
provide similar insights. History can provide some hints
about likely future actions [12], although the history of
Hep B adoption provided the Pneumococcal Vaccines
Accelerated Development and Introduction Plan
(Pneumo-ADIP [9]) with few clues for the introduction
of the pneumococcal vaccines, probably because of turn-
over of decision makers and different local champions
for the two vaccines.
Once countries are prioritized, they may express an
interest in conducting demonstration projects. As pro-
duct developers, PDPs are focused on generating evi-
dence from randomized, controlled clinical trials.
Often, however, such evidence is not sufficient for
adoption. After Phase 3 trials are complete, a deep
i n v e s t m e n tm a yb en e e d e di naf e wc o u n t r i e st oh e l p
generate examples or evidence that an intervention
works under real-world conditions (e.g., community
effectiveness). Although countries vary, such test cases
can boost the profile of a new intervention and result
in funding for roll out in further countries. PDPs may
help to build these early success cases and formulate
roll-out plans.
Strategies for establishing a local presence
Once a country has been prioritized, a PDP must decide
whether and how to establish a local presence. A PDP
with staff in an endemic country will have clear oppor-
tunities for improved information flow and closer
engagement with local stakeholders. However, PDPs
were primarily founded as research organizations, so
budgets for an endemic country presence are usually
driven by organizational nee d ss u c ha st h o s er e l a t e dt o
clinical trials. Aside from the Medicines for Malaria
Venture (MMV)’s office in Uganda, offices associated
with PDPs are not generally set up primarily for an
access-related purpose.
The options for establishing a local presence, listed
from most to least committed, include: country or regio-
nal offices, including with a partner organization; con-
sultants on partial retainer; sustained engagement with
existing committees or structures; engagement with ad
hoc committees or structures formed at the prompting
of a PDP; or ad hoc engagement with existing structures
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tees or meetings organized by WHO).
Local expertise, in the form of either PDP staff or con-
sultants, is critical to ensure a high quality interaction
with government officials and partner organizations. For
example, disease-specific and health systems knowledge,
and sufficient standing to collaborate with government
officials, physicians and researchers are important. Indi-
viduals with such skills can help to design and facilitate
local research and to provide local researchers and pol-
icy makers with PDP support for decision-making activ-
ities. Even beyond their own staff and consultants, PDPs
may also help to strengthen the pool of scientists, who
at the same time become stronger advocates within
their regions and countries; examples include MVI’s
annual Malaria Vaccine Advocacy Fellowship Program,
the Drugs for Neglected Diseases Initiative (DNDi)’s
research platforms, or Pneumo-ADIP and Hib Initia-
tive’s local advocates.
PDPs vary in their in-country presences (Table 3),
with the extent usually increasing as products move
further through the pipeline. PDPs within larger institu-
tions such as PATH are also able to leverage competen-
cies in multiple offices.
In sum, the rationale for the country presence of PDPs
has been driven by research and development (R&D) or
organizational needs (including limited funding), with
access activities building upon that presence. This sug-
g e s t st h a ta c c e s st e a m ss h o u l ds e e kt ob ep a r to fd e c i -
sions on where R&D activities are undertaken. PDPs
have also tended to take advantage of less costly means
for engaging with greater numbers of countries by work-
ing through existing committees and structures (includ-
ing WHO), developing new structures for sustained
engagement where feasible, or otherwise working
through ad hoc collaborations.
The essential role of partnership
For PDPs to achieve their goals, partnership is essential.
PDP access staff can initiate these partnerships by bring-
ing together different parties, such as scientists, manufac-
turers, regulators, and implementers. This combination
of perspectives from the scientific, commercial and public
health worlds can support more informed decision
making [34].
In order to reach multiple countries, the involvement
of WHO headquarters, country and, in particular, regio-
nal offices has been and will remain critical, particularly
for diseases such as HIV/AIDS, TB and malaria that
have a significant number of WHO staff. Regional
WHO offices can track the progress of multiple coun-
tries as they move through the multi-part decision pro-
cess. Table 4 describes possible partners, including
WHO, and some of their advantages and disadvantages.
Manufacturers have traditionally supported some
aspects of country decision-making and all the aspects
of product launch. However, many originator companies
may have limited experience of introduction into low
and middle income country markets (some Indian and
Chinese generics may be more established in these mar-
kets). Companies may also be concerned that they could
be perceived to be self-serving if supporting decision-
making around the introduction of a new product
directly in countries. Thus, the initial information shar-
ing and country decision making step will generally
require the involvement of other actors, including PDPs.
An interesting example of division of labor comes
from Uganda, where PATH, a not-for-profit that has
Table 3 PDP offices in endemic countries
PDP Offices in endemic countries
Drugs for Neglected Disease Initiative
(DNDi)
Kenya, Brazil, Democratic Republic of the Congo, India, Malaysia, where it may be as small as a 1-person
office
PATH Malaria Vaccine Initiative (MVI) PATH office in Kenya with dedicated MVI program staff, plus PATH offices that can be called upon such as
in Senegal, Ghana, Ethiopia, Uganda, Tanzania, Zambia, and South Africa
Medicines for Malaria Venture (MMV) Uganda, initially for pilot of AMFm (Affordable Medicines Facility - malaria), now for regional interactions
on guideline revisions
Institute for One World Health (iOWH) India
Global Alliance for TB Drug
Development (TB Alliance)
South Africa - focused on clinical trial conduct rather than access
Foundation for Innovative New
Diagnostics (FIND)
India, Uganda
International AIDS Vaccine Initiative
(IAVI)
India, Kenya, South Africa
Aeras Global TB Vaccine Foundation
(Aeras)
South Africa
International Partnership for
Microbicides (IPM)
South Africa
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Page 7 of 12worked extensively as a PDP, is supporting a demonstra-
tion project for human papilloma virus (HPV) vaccines
(E. Mugisha, pers. comm.). Before any activities started,
PATH signed a Memorandum of Understanding (MOU)
with the Government of Uganda (GoU) to specify who
would do what. The GoU committed to provide health
services delivery infrastructure, human resources in the
districts, and EPI staff for delivery of the vaccine.
The two PATH technical staff members, located in the
WHO Uganda office, provided technical and logistical
support. PATH also provided transport allowances (but
no per diems) to health workers in the field and funded
local university researchers to conduct the formative
research and operations research. WHO and UNICEF
participated in a technical advisory committee set up by
the Ministry of Health (MoH) to oversee the demonstra-
tion project, and also helped with monitoring of
vaccination. The relevant pharmaceutical company
(GlaxoSmithKline Biologicals (GSK)) donated and
shipped vaccines to Uganda, but had no other role in
the project. UNFPA and other stakeholders provided
input on reproductive health issues, and NGOs (e.g.,
CARE and Save the Children) helped with mobilization
in the districts. Thus, PATH served as the glue across
the various organizations in support of the MoH.
Challenges to PDP implementation
There are many challenges for PDPs in supporting
country decision making. Creating a success story in
one location is certainly important, but just getting the
process right in one country won’t necessarily allow
replication, as each country is different. The PDP, how-
ever, is unlikely to have the resources to replicate the
same breadth of activities with all endemic countries.
There is also an issue of managing expectations.
Country decision making is driven by the country, not
the PDP. Conveying this idea of public sector policy
change to R&D staff, PDP boards and funders can be
challenging. Furthermore, PDP boards often think that
local implementation partners can do it all, so local
engagement by the PDP is not necessary. But partners
are focused on many other issues, and often do not
have the full depth of information on a given
intervention.
Finally, optimal engagement timelines are unclear.
Advance planning is risky as product timelines are
uncertain, but without early engagement (e.g. 5 years
pre-licensure), country decision making may be delayed
and products will sit unused on shelves. In terms of
PDP access budgets, a critical step will be to address the
number and cost of Phase 4 studies, determine who will
bear the burden of financing them (e.g., donors and
PDPs, manufacturers, countries or some combination),
and define models to bring those costs down.
Specific PDP approaches for supporting country
decision making activities
Despite these challenges, successful PDP support of
country decision making is possible. The case studies
below illustrate that PDPs have taken many distinct
approaches to facilitating country decision making.
These are examples of what has been done, rather than
normative descriptions of what would be ideal. They
were selected to represent a range of modalities (e.g.,
vaccine, drug, and insecticide) and disease areas, and the
kinds of activities conducted at different stages of the
decision process (presented below in roughly chronolo-
gical order). Different PDPs have undertaken a range of
activities, such as those shown in Tables 1 and 2, with
this selection depending on needs identified by each
PDP, typically in consultation with partners like WHO
and countries. Not surprisingly, the more extensive
experience generally lies with the PDPs who have
approved products.
Table 4 Partners who can support country decision making, in collaboration with PDPs
Partner Advantages Disadvantages
Multilaterals such as WHO Extensive reach and impartiality Limited staff and restricted funding; May be
overwhelmed by other initiatives and thus lack time
and resources to devote to new interventions
Organizations dedicated to new product access, such
as those funded by GAVI (e.g., Hib Initiative,
Accelerated Vaccine Introduction Initiative (AVI))
Dedicated funding for access activities Typically have a multi-country remit which limits
depth of engagement in individual countries
Local academia, researchers and/or professional
organizations
Close to in-country processes, needs
and data; Credible with local policy-
makers
May not have a broad view of a problem; May be
influenced by personal research interests
NGOs Some have specific expertise in new
product introduction
May require funding specific to the new product to
support their activities, and may not be involved in
official decision-making bodies
Pharmaceutical and/or manufacturing partners Product-specific expertise, regulatory
expertise, and in some cases extensive
sales networks in some markets
May be seen as a biased source of decision making
information; may lack experience in the disease
and/or in low and middle income settings
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For DNDi, country engagement begins with the identifi-
cation of needs by and with endemic country stake-
holders. Certain key research organizations in endemic
countries contributed to DNDi’sf o u n d i n g ,a r er e p r e -
sented on its Board of Directors, and greatly inform the
definition of needs and of the related Target Product
Profiles (TPPs). These organizations also facilitate clini-
cal and intervention trials and, ultimately, national deci-
sions on adoption.
Three additional PDPs, whose activities are outlined
below, do not yet have products approved by regulatory
agencies but nonetheless conduct activities related to
country decision making. For malaria vaccines, MVI
initiated a 3 year process with countries, WHO and, in
the later stages, the Roll Back Malaria Partnership
(RBM) to develop decision-making frameworks, initially
for 9 individual countries and then for the African
region [33]. The final framework builds upon existing
WHO guidelines [22], and lays out what data are needed
from different sources (global vs national), in different
thematic areas (disease burden, other malaria interven-
tions, impact, financial, efficacy, safety, programmatic,
sociocultural), and at different times (pre-licensure,
licensure, and post-licensure); it also notes whether each
is essential or desirable. It provides a similar framework
for policy processes.
The framework process has and will structure dialo-
gues around malaria vaccines with countries around
technical issues. In some countries, it has led to the for-
mation of ongoing structures that have begun to collect
data to inform an eventual decision (e.g., technical
working groups - MVI now sponsors three of these).
In contrast to MVI, the Global Alliance for TB Drug
Development (TB Alliance) is entering an area that has
existing products. There was, however, relatively little
analysis of the market, of decision making, or of how
new products would be considered. TB Alliance there-
fore focused on conducting sequential stakeholder stu-
dies in the following areas: the size and structure of the
existing TB drug market; what local stakeholders want
from a new TB regimen; how the experience with past
TB regimen changes can inform future approaches; and
what producers and products are dominant in the pri-
vate sector. These studies helped to identify issues and
categories of data relevant for future country decision
making [12,31], initiate engagement with local stake-
holders, provide opportunities for the promotion of regi-
men change issues in international fora, and frame
conversations with local stakeholders during TB Alliance
participation in WHO review missions. Finally, the find-
ings of each study influenced the design and content of
the next, and provided essential feedback for the
research and development team [2]. TB Alliance
selected this approach due to the opportunities and
challenges presented by the availability of existing TB
treatment regimens and partnerships.
The long-term aim of IVCC is to facilitate the devel-
opment and introduction of new insecticides. Already,
however, IVCC is engaging country decision makers to
address an identified gap in field implementation - the
monitoring and evaluation of vector control programs.
This gap is addressed via IVCC’s Malaria Decision Sup-
port System (MDSS), which is used to track clinical and
survey data and insecticide resistance (T. McLean, pers.
comm.). This tool is applicable to a wide range of dis-
eases and, in addition to monitoring and evaluation, it
supports the management of advanced insecticides, and
decision making on adopting new vector control pro-
ducts. Based on existing partnerships with the ministries
of health, IVCC has validated the methodology in 3
countries - Mozambique, Malawi, and Zambia - with
varied infrastructure and ecological environments; it is
now planning wide-ranging implementation. As a cen-
tral objective, the MDSS should be adopted and owned
by the national malaria control program and serve their
information needs.
Country consultations and regional meetings
Early and frequent consultations with countries are
essential for the development of products that are suited
to end users [2]. For DNDi, input is channeled via dis-
ease platforms, which were formed to assist and
strengthen clinical research around specific diseases in a
geographic area, e.g., Visceral Leishmaniasis (VL) in East
Africa, sleeping sickness in West Africa, and Chagas
Disease in Latin America. These platforms include
country program staff, researchers, regulatory officials,
NGOs and WHO and meet twice a year. Platform mem-
bers became natural partners for country decision mak-
ing as they gather relevant information on in-country
issues, programs, and processes and convey key infor-
mation to in-country decision makers.
The Pneumo-ADIP (now part of the International
Vaccine Access Center (IVAC)) built on experience with
Hib and Hepatitis B vaccine introductions to support
pneumococcal vaccine introduction [9]. Under the
Pneumo-ADIP, the establishment of surveillance net-
works had two positive outcomes: it provided the
requested data on projected coverage and impact and,
via annual investigators’ meetings, led to the identifica-
tion of local advocates. In addition, regional meetings
organized in collaboration with WHO provided an
opportunity to check back in and to move countries to
put their decisions and proposed actions on paper by
presenting their conclusions in front of others (L. Pri-
vor-Dumm, pers. comm.). These meetings included EPI
managers, directors of health services, researchers,
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financing people from MoH or other ministries, and
were a particularly useful mechanism to support deci-
sion-making in countries not directly targeted through
other interactions.
MMV and its drug development partners have also
made extensive use of country-level dialogues such as
subregional meetings (of WHO AFRO and Roll Back
Malaria) and, in select cases, day-long workshops (G.
Jagoe, pers. comm.). These provide opportunities to give
product-specific briefings and to reinforce recommenda-
tions of normative entities (primarily WHO) in terms of
best practice for the development and revision of treat-
ment guidelines and for the correct use of new, quality
medications in combination with proper diagnosis (case
management). Longer-term programmatic collaborations
in specific-countries are very limited; the focus is on any
initiative (e.g., piloting of an affordable medicines private
sector subsidy in Uganda) that address specific access
challenges and could serve as guiding lights for policy
makers and funders across the larger stage of all malaria
endemic countries. In terms of impact, as of September
2010, almost 42 million treatments of Coartem
® Disper-
sible (co-developed with MMV) had been delivered to
32 countries [37].
Regional meetings have been convened by the TB Alli-
ance and partners to gain consensus around regulatory
issues [38]. Existing TB drugs were developed more than
40 years ago, in a very different regulatory environment.
Agreement was needed on the regulatory approach to
development of not just individual new drugs, but new
regimens. With the participation of national TB program
managers in these meetings, these individuals became
part of the conversation about what types of evidence
would be available for decision making.
Implementation studies as a bridge to adoption
When existing evidence is insufficient, implementation
studies may be necessary. In India, the Institute for One
World Health (iOWH) has supported studies to gener-
ate data for advocacy and decision making on VL treat-
ment and elimination. In collaboration with a research
institute of the Government of India, they documented
the incidence of VL, the financial burden of disease,
households’ willingness and ability to pay, and treat-
ment-seeking behaviors in both public and private sec-
tors (R. Sarnoff, pers. comm.). In addition, building on
the necessary Phase 3 study, iOWH sponsored a Phase
4 study with an effectiveness module that provided
training, clinical support, and guidance on pharmacov-
igilance reporting, and demonstrated effective delivery in
public and private facilities. The clinical trial investiga-
tors formed a core constituency for local advocacy for
improved products.
At the national level, iOWH leadership engaged with
key stakeholders in the Indian government, World Bank
and WHO to inform them of the progress of the stu-
dies, identify their key questions and concerns, and
address future funding issues. Training modules and
community communication models were developed for
smooth transfer to the national authorities.
DNDi has also used intervention or field trials as an
essential step to demonstrate feasibility and generate
necessary data for adoption into national programs (F.
Camus-Bablon, pers. comm.). For example, Brazil con-
ducted a 25,000-subject malaria intervention trial prior
to adopting artesunate andm e f l o q u i n e( A S M Q )f o r
treatment of falciparum malaria in the Amazon basin.
The trial monitored the effects of ASMQ introduction;
during the study, a significant impact on malaria cases
and related hospitalization also resulted from a more
rational use of complementary resources such as insecti-
cides, a detection and reporting system, and the training
of local human resources. In this study, one year
after the introduction of the ASMQ fixed-dose combi-
nation (FDC) and the treatment of 17,000 patients,
P. falciparum malaria cases were reduced by nearly 70%
and malaria-related hospitalizations dropped by over
60%. Following the study, the Brazilian National Pro-
gram updated the national malaria treatment guidelines
and introduced ASMQ FDC as the first line treatment
in the region. Advocacy is also a key component of
DNDi implementation work, to inform both interna-
tional audiences and endemic countries.
In some areas, DNDi relies on pharmaceutical and
other international partners. For example, WHO
Neglected Tropical Diseases (NTD) department and
Médecins Sans Frontières (MSF) are key drivers for the
adoption of nifurtimox-eflornithine combination therapy
(NECT) for the treatment of sleeping sickness, which,
within a year, has been adopted in the national treat-
ment policy of nine endemic countries and ordered by
six. Sanofi-Aventis (SA), within two years of WHO pre-
qualification, was planning to distribute 50 million arte-
sunate-amodiaquine (ASAQ) treatments in 2010. Today,
ASAQ is registered in 27 African countries and in India.
SA is conducting a 15,000 patient pharmacovigilance
program in partnership with DNDi and MMV in Ivory
Coast, and developed a specific package for social inter-
ventions and home based management programs.
Evaluation of impact
There are significant challenges in estimating the impact
of PDPs on country decision making. First, most PDPs
are relatively young, being established in the last
10 years. Given the time required to develop a product,
many have not yet had products launched, and the pro-
duct launches that have occurred are recent. Second,
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in particular, whether to focus on usage (e.g., number of
individuals treated; see the data on new product usage
noted in this paper) or on process (the number of coun-
tries conducting a policy process and reaching the deci-
sion that is best for their particular situation; see [39]
for an example). Third, if a product is suboptimal - too
expensive, insufficiently efficacious, or too difficult to
use, for example - it is unlikely to be rescued by PDP
support of country decision making, even if those sup-
port activities are well executed. In other words, success
under the first ("usage”) definition is only likely when
the new product continues to meet identified country
needs. This is why access input is essential throughout
the product development process [2].
There have, however, been efforts by PDPs to define
metrics of success and to evaluate PDP work in support
of country decision-making. For impact using the “pro-
cess” definition of success, one example is the malaria
vaccine decision-making framework [39]. The develop-
ment of this framework has been independently evalu-
ated [40]. Out of 84 respondents from 10 countries, 90%
felt that the framework developed will be extremely or
very useful in preparation for a decision (i.e., in deciding
what activities to undertake prior to having a licensed
product), and 88% indicated the same for taking a deci-
sion after a vaccine is licensed. Facilitators were reported
to be neutral instead of supporting one product.
A 2007 study by the GAVI Alliance tried to quantify
the impact of the Pneumo- and Rotavirus ADIPs and Hib
Initiative as compared to what may have happened if
they had not been in place [41]. The authors found that
the Pneumo-ADIP is likely to shave at least five years off
the time from development to availability of vaccines in
the poorest countries, and that the work of the Rotavirus
ADIP may result in the poorest countries accessing vac-
cines only one year after availability in the developed
world, which is years and decades shorter than histori-
cally. Based upon this, the authors reported “value in
terms of lives saved and hospitalizations averted.”
Given the constraints noted above, the current paper
does not aim to provide a rigorous evaluation of PDP
impact and strategies, but instead provides a situation
analysis, reflecting the range of strategies undertaken by
PDPs and detailing the rationale behind their choice. It
is clear that having no engagement specifically around
new products leads to lengthy delays in availability [1].
At the same time, it is too early to determine the opti-
mal strategies for each situation and type of interven-
tion. However, the current analysis provides an
important baseline or reference point for a later impact
analysis of PDP work on access.
Conclusion
Ac o u n t r y ’s decision to adopt a new health technology
requires more than the existence of a good product. In
low and middle income settings, a wide range of organi-
zations can support country decision making. The role
of PDPs in this process is based on the PDPs’ vision to
see public health impact from the products they
develop, and on their intimate familiarity with the pro-
ducts under discussion.
A PDP as a whole can cover a wide spectrum of activ-
ities ranging from basic research to implementation of
interventions. At the implementation end of this spec-
trum, there is no single definition of where the PDP
role ends, as the technical needs and available partners
in endemic countries vary for each intervention. How-
ever, as more PDP-related products progress, additional
experience will assist in defining the areas in which
PDPs are effective and should be held accountable. Fun-
der, partner and country participation in the develop-
ment of improved means to evaluate the relative roles
and impact of PDPs will also be important. Building on
the insights described here, PDPs, partners and country
stakeholders can continue to provide critical support for
decisions on interventions that will ultimately decrease
the global burden of disease.
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